.After raising $170 thousand back in February, metabolic disease-focused BioAge Labs has actually filed to debut on everyone market.The Eli Lilly-partnered biotech plan to list on the Nasdaq under the sign "BIOA," according to documents submitted with the Securities and also Exchange Commission. The business has not publicly shared an expected monetary volume for the offering.The clinical-stage firm boasts lead applicant azelaprag, a by mouth provided small molecule slated to get in period 2 testing in combo with semaglutide-- marketed by Novo Nordisk under brand Wegovy for weight-loss-- in the very first fifty percent of next year. Semaglutide is actually likewise sold as Ozempic and Rybelsus through Novo for diabetic issues.
Apelin receptor agonist azelaprag is actually designed to incorporate properly with GLP-1 medicines, enhancing effective weight loss while protecting muscle mass. The investigational medication was actually found to become well-tolerated one of 265 people across 8 stage 1 tests, depending on to BioAge.Previously, BioAge garnered the assistance of Lilly to operate a test incorporating azelaprag along with the Large Pharma's GLP-1/ GIP receptor agonist tirzepatide, which is marketed for diabetic issues as Mounjaro and also Zepbound for effective weight loss. The partners are actually currently carrying out a stage 2 trial of azelaprag as well as tirzepatide, with topline results anticipated in the 3rd fourth of 2025.The biotech is actually additionally planning a the hormone insulin sensitivity proof-of-concept test evaluating azelaprag as a monotherapy in the initial fifty percent of following year to assist prospective indicator expansion. On top of that, the provider plans to ask the FDA for approval in the 2nd fifty percent of 2025 to launch individual screening for an NLRP3 inhibitor targeting metabolic conditions and neuroinflammation.BioAge's foreseed move to the public market observes a small uptick in organized biotech IPOs coming from Bicara Therapies as well as Zenas Biopharma. Zooming out, the recent IPO yard is actually a "combined image," with high-quality firms still debuting on everyone markets, simply in minimized amounts, according to PitchBook.